Journal
FRONTIERS IN IMMUNOLOGY
Volume 3, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2012.00220
Keywords
T cell regulation; protein kinases; PKC isotypes; immune disease therapy
Categories
Funding
- FWF Austrian Science Fund [SFB-021, T264-B13, P19505-B05, P25044]
- Austrian BM:WF
- European Community Program SYBILLA [HEALTH-F4-2008-201106]
- Austrian Science Fund (FWF) [T 264] Funding Source: researchfish
Ask authors/readers for more resources
It is well established that members of the protein kinase C (PKC) family seem to have important roles in T cells. Focusing on the physiological and non-redundant PKC functions established in primary mouse T cells via germline gene-targeting approaches, our current knowledge defines two particularly critical PKC gene products, PKCO and PKCa, as the flavor of PKC in T cells that appear to have a positive role in signaling pathways that are necessary for full antigen receptor-mediated T cell activation ex vivo and T cell-mediated immunity in vivo. Consistently, in spite of the current dogma that PKCO inhibition might be sufficient to achieve complete immunosuppressive effects, more recent results have indicated that the pharmacological inhibition of PKCO, and additionally, at least PKCa, appears to be needed to provide a successful approach for the prevention of allograft rejection and treatment of autoimmune diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available